|
Ipsen - Comparative Business Analysis Snapshot
Business Description
Ipsen. The Group's principal activity is to develop and distribute pharmaceutical products. The Group develops innovative drugs used in therapeutic areas in oncology, endocrinology and neuromuscular disorders. Some of their products include Decapeptyl, Somatuline, NutropinAq, Autogel, Forlax, Tanakan, Testim and Dysport. The Group also offers products on primary care which includes the areas of gastroenterology, cardiovascular and cognitive disorders. The Group operates throughout the world, In 2008, the Group acquired Vernalis Pharmaceuticals and Tercica Inc.
Competitor Analysis
This analysis compares Ipsen with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
